Answer
The mean terminal elimination half-life of risankizumab ranged from 28 to 29 days in Phase 3 studies in patients with psoriasis.
Sources for this answer
- Skyrizi 150 mg solution for injection in pre-filled penAbbVie Ltd · emc · SmPC §5.2 Pharmacokinetic properties · Version 12Document updated
Sources checked